Investment analysts at Wedbush boosted their FY2025 earnings estimates for shares of Fennec Pharmaceuticals in a research ...

In-theater advertising company National CineMedia Inc. is well-positioned to reap the benefits of cinema’s unique proposition ...

Arvinas (NASDAQ:ARVN – Get Free Report) was downgraded by analysts at Wedbush from an “outperform” rating to a “neutral” ...

Wedbush said Friday it expects North American box office to rise at least 7% in 2025, with double-digit growth in the second ...

Stacey Winter joined Wedbush Securities in 2002 and currently serves as managing director, head of equity sales and head of ...

Arvinas (ARVN) stock faces a downgrade after underwhelming trial data for breast cancer drug vepdegestrant developed with ...

Wedbush raised the firm’s price target on Rubrik (RBRK) to $80 from $75 and keeps an Outperform rating on the shares. The firm notes Rubrik ...

Fintel reports that on March 12, 2025, Wedbush downgraded their outlook for Arvinas (NasdaqGS:ARVN) from Outperform to ...

"We see continued strong demand," Rubrik co-founder and CEO Bipul Sinha told me on Yahoo Finance on Friday. Sinha's comments ...

It’s been a bad month for the stock market. But it’s been a terrible month—in fact, a terrible year—for Tesla. Even after ...

US stocks slid Thursday and the S&P 500 closed in correction, down more than 10% from its record high in February, as ...

Despite the recent sell-off in tech stocks, analysts at Wedbush believe that this downturn is temporary and that AI leaders ...